Every 10-Q that FOXO TECHNOLOGIES A (FOXO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FOXO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FOXO filings page.
FOXO Technologies Inc. reported net revenues of $9.9 million for the six months ended June 30, 2026, up from $8.4 million in 2025, while second‑quarter net revenues declined to $4.7 million from $5.2 million. A large non‑cash forfeiture under its Management Contingent Share Plan and a severance reversal drove income from operations of $8.5 million and net income attributable to FOXO of $6.7 million, versus a $1.1 million loss a year earlier.
The balance sheet remains highly stressed. Cash and cash equivalents were only $58,409 with a working capital deficit of $35.9 million, total liabilities of $45.0 million, and total stockholders’ equity of $0.9 million. Debt rose to $17.2 million, all classified as current, and many promissory notes are in default and accruing penalties; past‑due payroll taxes and related penalties total about $7.4 million. Management concludes that these conditions, along with dependence on external financing, raise substantial doubt about the ability to continue as a going concern.
During the quarter FOXO and its founder entered a Strategic Technology License Agreement granting his controlled entity an exclusive license to commercialize FOXO Labs’ epigenetics IP in exchange for a 3% royalty (capped at $1.3 million) and a 10‑year option to acquire majority ownership of FOXO Labs, while resolving prior disputes and severance obligations. On June 30, 2026, FOXO implemented a 1‑for‑3,000 reverse stock split, following earlier reverse splits in 2025.
FOXO Technologies Inc. reports Q1 2026 results with net revenues of $5.17 million, up from $3.17 million a year earlier, mainly from its healthcare and life science services businesses. Despite higher revenue, FOXO recorded a net loss to common stockholders of $1.74 million.
The company ended March 31, 2026 with $65,896 in cash and a working capital deficit of $27.1 million, and it carries $8.61 million of current debt. Management discloses that these conditions and ongoing losses raise substantial doubt about FOXO’s ability to continue as a going concern absent additional financing and improved cash flow.
FOXO Technologies Inc. filed its Q3 2025 report, showing sharp top-line growth alongside continued losses and liquidity pressure. Net revenues were $3,548,352 for the quarter, up from $1,196,557 a year ago, and $11,936,645 for the nine months, helped by healthcare operations and $3.0 million from Tennessee’s Hospital Improvement Plan. Loss from operations was $(859,821) in Q3, and net loss attributable to FOXO was $(3,014,545) for the nine months.
After large deemed preferred dividends, net loss to common stockholders was $(14,142,882) in Q3. Cash was $628,557 at September 30, 2025, with a working capital deficit of $24.5 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern without new financing. Total assets were $52.1 million and stockholders’ equity $20.1 million.
The company’s Class A common stock was delisted from NYSE American on August 22, 2025 and began trading on OTC Markets on August 13, 2025 under “FOXO.” Reverse stock splits of 1‑for‑10 (April 28, 2025) and 1‑for‑1.99 (July 27, 2025) were implemented. Shares outstanding were 108,866,549 as of September 30, 2025; as of November 7, 2025, Class A shares outstanding were 526,520,303.
FOXO Technologies, Inc. reported continued operating losses and liquidity strain for the six months ended June 30, 2025. The company had a working capital deficit of $27.3 million and only $0.3 million of cash and cash equivalents at June 30, 2025. Cash used in operating activities for the six months was $3.7 million. Total debt, net of discounts, was $11.2 million and total stockholders' equity was $13.7 million. Goodwill increased to approximately $31.3 million. The healthcare segment recorded meaningful changes in recognized net revenues after estimating contractual allowances: healthcare net revenues were $5.2 million for the three months and $8.4 million for the six months ended June 30, 2025, compared with minimal prior-year amounts. The period included material financing and capital-structure events, including exchanges of Senior PIK Notes into Series B Preferred Stock and the issuance of Series A Preferred Stock (3,400 shares for gross proceeds of $3.35 million). The filing discloses multiple notes and defaults, related-party balances, accrued liabilities including severance of $2.17 million, and legal/settlement items. Management disclosed ongoing discussions with creditors on extensions and various subsequent conversions and exchanges of preferred stock into common shares.
FOXO Technologies Inc. reports material balance sheet and financing activity tied to 2024 acquisitions and debt restructurings. The company had a working capital deficit of $30.6 million and only $16,907 in cash and cash equivalents as of March 31, 2025. For the three months ended March 31, 2025, FOXO reported a net loss attributable to common stockholders of $788,583, or $0.73 per Class A share; comparable prior-period weighted average shares and loss per share are shown in the filing.
The company recorded a $1.86 million gain from extinguishment of Senior PIK Notes after exchanging those notes into Series B Preferred Stock. Healthcare net revenues for the quarter were $3.2 million after estimated contractual allowances. Total debt (net of discounts) was $6.0 million with multiple notes and related-party payables disclosed, several in default or subject to negotiation; goodwill of approximately $25.5 million relates to the Myrtle and RCHI acquisitions and additional purchase-price contingencies remain within the one-year measurement period.